Control of cell growth and division by the p53 tumor suppressor protein requires its abilities to transactivate and repress speci®c target genes and to associate in complex with other proteins. Here we demonstrate that p53 binds to the E1A-regulated transcription factor p120E4F, a transcriptional repressor of the adenovirus E4 promoter. The interaction involves carboxy-terminal half of p120E4F and sequences located at the end of the sequence-speci®c DNA-binding domain of p53. Ectopic expression of p120E4F leads to a block of cell proliferation in several human and murine cell lines and this eect requires the association with wild-type (wt) p53. Although p120E4F can also bind to mutant p53, the growth suppression induced by overexpression of the protein is severely reduced in a cell line that contains mutant p53. These data suggest that p120E4F may represent an important element within the complex network of p53 checkpoint functions.
Introduction
The product of the p53 tumor suppressor gene plays a pivotal role in controlling the onset and progression of human neoplasias, as is underlined by the high incidence of p53 mutations found in a broad spectrum of human cancers (Hollstein et al., 1991) . The central role of p53 as the safeguard of the genome integrity arises from its ability to respond to a variety of events that can lead to uncontrolled proliferation (for review see Giaccia and Kastan, 1998; Ko and Prives, 1996; Levine, 1997) .
Several types of DNA damage, as well as other stress conditions, like hypoxia or ribonucleotide depletion, activate p53 leading to the transactivation of target genes which mediate, at least in part, p53-dependent growth arrest and apoptosis Giaccia and Kastan, 1998; Graeber et al., 1996; Linke et al., 1996) . Activated p53 can also repress the transcription of various genes and this function may also contribute to its downstream eects (Murphy et al., 1996; Wang et al., 1997) . These two functions of p53 may be mechanistically distinct. Transcriptional activation occurs through the direct binding of p53 to speci®c promoter elements, whereas repression may additionally require the association with other promoter-bound transactivators or repressors (Murphy et al., 1996; Ori et al., 1998) .
The overall complexity of p53-dependent functions requires association of the protein with multiple cellular factors (Haupt et al., 1995; Ruaro et al., 1997; Wang et al., 1996) . Some of them act on p53 to modulate its functional activation in response to various signals (Giaccia and Kastan, 1998) , to alter its DNA binding (Jayaraman et al., 1997) and transcriptional activities (Gu et al., 1997; Levine, 1997; Lill et al., 1997) , or its ability to modulate DNA repair (Wang et al., 1995) . In some other cases these proteins are targeted by p53 and the resulting complexes in¯uence the eciency of its checkpoint functions, as observed for the association of p53 with the XBP and XPD helicases, components of the TFIIH transcription/DNA repair complex, which is also involved in p53 mediated-apoptosis (Wang et al., 1996) . The ability of p53 to associate with these cellular partners may be reduced or absent in transformed cells expressing mutant p53 (Iwabuchi et al., 1994) . In many cases, however, mutant p53 can still bind to these proteins, although the complexes are functionally inactive (Wang et al., 1995) .
In searching for new p53 interacting proteins, we isolated the transcription factor p120E4F (Fernandes and Rooney, 1997) in a yeast two-hybrid screen. p120E4F is one of two related zinc-®nger proteins that dierentially regulate the adenovirus E4 promoter in an E1A-dependent manner (Fernandes and Rooney, 1997) . The full-length protein, p120E4F, represses this promoter in the absence, but not in the presence of E1A. The other E4F protein, p50E4F is a proteolytically derived amino terminal fragment of p120E4F that was shown to stimulate the E4 promoter when coexpressed with E1A. Moreover, when ectopically expressed in mouse ®broblasts, p120E4F, but not p50E4F, blocked cell proliferation by inducing a cell cycle arrest near the G1/S transition (Fernandes et al., 1998 ).
Here we demonstrate that E4F associates both in vitro and in vivo with p53 in mouse and in human cells. The association with p53 occurs through residues that are speci®c to p120E4F and is required for its growth suppression activity. p120E4F may therefore represent a novel p53 cellular partner that contributes to its checkpoint functions.
Results

Isolation of E4F as a candidate p53 associated protein
The yeast two-hybrid screen (Gyuris et al., 1993 ) was employed to identify proteins able to associate with the p53H175 hot spot mutant. Approximately 3.5 million independent transformants were screened and 27 single clones were isolated and analysed for their ability to bind also wt p53 (LexAwtp53, aa 74-393). Sequence analysis revealed that one of the clones which interacted both with mutant and wt p53, corresponds to the carboxy-terminal half (starting from aa 350) of the E1A-regulated transcription factor p120E4F (Fernandes and Rooney, 1997) . Structurally, p120E4F contains six zinc-®nger motifs which are clustered in two separate regions: two motifs are contained within an amino terminal domain that is also present in p50E4F, while the remaining four are grouped within a central region (aa 436-568) found only in the fulllength protein (Fernandes and Rooney, 1997) . The isolated clone (E4FD350) encodes the entire central zinc-®nger domain and all further carboxy-terminal residues that are speci®c to p120E4F (Figure 1a) .
To verify the interaction in vitro, the isolated cDNA was expressed in bacteria as GST-fusion protein (GST-E4FD350) and tested in a pull down experiment. Puri®ed GST-E4FD350 or GST proteins were immobilized on GSH-Sepharose beads and incubated with in vitro translated p53H175, p53H273 and wt p53 proteins (Figure 1b ). In agreement with the data obtained in the yeast two-hybrid system, p53wt, p53H175 as well as p53H273, were speci®cally retained on beads coupled with GST-E4FD350 (lanes 7, 8 and 9). A speci®c interaction was also observed with in vitro translated mouse wt p53 protein (not shown). These data therefore demonstrate that E4F can directly associate with p53.
E4F associates with p53 in vivo
A longer clone, missing only the ®rst 60 amino acids of p120E4F (E4FD60) was isolated from a human placental cDNA library and inserted into the expression vector pcDNA3, downstream of a START codon and a contiguous HA epitope (pcDNA3HA). This construct was used in transient transfection experiments to demonstrate the association between E4F and p53 within murine Balb/c Val5 (Val5) ®broblasts (Ginsberg et al., 1991) . This cell line stably expresses the temperature sensitive murine p53 valine 135 mutant, which exhibits a wild-type conformation at 328C (permissive temperature) and a mutant conformation at 378C (non-permissive temperature) allowing to directly test the binding anity of E4F to both p53 forms within the same cells. Subcon¯uent growing cells maintained at 378C were transfected with pcDNA3HAE4FD60 or with control plasmid (pcDNA3). Twelve hours after transfection, cells were split in two plates and incubated for 24 h at the permissive or non-permissive temperature. Lysates of cells maintained at 328C were immunoprecipitated with Pab 246, which recognizes wt p53, whereas extracts from cells grown at 378C were immunoprecipitated with the mutant-speci®c antibody Pab 240. Immunoprecipitates were subjected to Western blot analysis with an antiserum raised against FAP3, the murine homologue of E4F (Fognani et al., 1993) . This antiserum has been shown to recognize both human and murine E4F proteins (Fernandes and Rooney, 1997) . As shown in Figure 2a , ectopically expressed HA-E4FD60 associated equally well with wt and mutant murine p53 in Val5 cells (lanes 4 and 8). Similar results were obtained when FAP3 was transiently overexpressed in the same cell line ( Figure  2b , lanes 4 and 8).
To con®rm the association in human cells, the fulllength E4F cDNA (E4F2.5K; Fernandes and Rooney, 1997) cloned in pcDNA3HA, was transiently overexpressed in U2OS, a human osteosarcoma cell line expressing wt p53. Cell lysates were immunoprecipitated with the anti-p53 monoclonal antibody DO-1, then blotted with anti-HA antibody. As shown in Figure 2c , p53 associated with ectopically expressed p120E4F. Complex formation was also detected in cells transfected with pcDNA3HAE4FD350, a construct expressing E4FD350 (not shown).
Finally, to establish the existence of a complex of endogenous p53 and p120E4F proteins, cellular extracts from untransfected U2OS were immunoprecipitated with the E4F-speci®c antibody N4 (Fernandes and Rooney, 1997) or with preimmune sera as a control. Immunocomplexes were then resolved on SDS ± PAGE and blotted for Western analysis with DO-1 antibody. As shown in Figure 2d , endogenous E4F was immunoprecipitated from U2OS cell lysates in complex with endogenous wt p53.
Taken together, these results clearly demonstrate that p120E4F can form a complex in vivo with wt and mutant p53, both in human and murine cells. S-labeled wt (p53 wt) or mutant (p53H273 and p53H175) p53. A fraction of the input (25%) of in vitro translated products (lanes 1, 2 and 3) as well as the GST (lanes 4, 5 and 6) and 8 and 9) were resolved on SDS ± PAGE and visualized by autoradiography
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To identify the region of p53 involved in the interaction with p120E4F, we produced various wt p53 deletion mutants by in vitro translation and tested them for binding to GST-E4FD350 in a pull down experiment ( Figure 3 ). As summarized in Figure 3b , E4F bound to all the C-terminally truncated p53 proteins used, however we observed signi®cant differences in the eciency of interaction. While the fulllength protein, capable of tetramerization, bound strongly to GST-E4FD350 (Figure 3a , lane 3), tr355, that forms dimers in solution (Tarunina and Jenkins, 1993) exhibited a weaker interaction (lane 6), suggesting that the quaternary structure of p53 may in¯uence the association. Supporting this hypothesis, the two monomers, tr338 and tr298, are more impaired in their ability to bind to GST-E4FD350 (lanes 9 and 12, respectively). The interaction with tr298 was very weak, suggesting that the E4F-binding region is located near to the end of the core domain (mapped between residues 102 and 292; Pavletich et al., 1993; Bargonetti et al., 1993; Wang et al., 1993) . In agreement with this assumption, a construct containing the tetramerization domain and the unspeci®c DNA-binding region but lacking the core domain (p53 Ct) was unable to interact (lane 18). An amino-terminal deletion mutant of p53 (p53D256), that overlaps 42 amino acids with tr298 and contains the tetramerization domain, interacted strongly (lane 15), demonstrating that binding to E4F requires amino acids 256 ± 294 of human p53.
E4F does not aect the transactivation capability of wt p53
To test whether the transactivation activity of p53 was aected by the interaction with E4F, the p53-null SaOS-2 cells were transfected with the pG13CAT reporter plasmid (Kern et al., 1992) together with vectors encoding for human wild-type p53 (p53 wt) and HA-tagged full-length or amino terminally truncated E4F (HA-E4F2.5K and HA-E4FD350, respectively). An HA-tagged, carboxy terminal fragment of human p53 (p53 Ct; residues from 294 ± 393) was used as a positive control, since a corresponding fragment derived from the murine protein has been shown to aect wt p53 functions in a dominant negative manner . Eight hours after removing the precipitates, cells were split in two plates and grown for 24 h at the permissive temperature (328C, p53 wt conformation) or at the non-permissive temperature (378C, p53 mutant conformation). Immunoprecipitation was performed by using wt p53-speci®c antibody (Pab 246) on cell lysates obtained from cells maintained at 328C and mutant p53-speci®c antibody (Pab 240) for cells grown at 378C. Immunocomplexes were resolved on a 10% SDS ± polyacrilamide gel and subjected to Western blot analysis with anti-FAP3 antiserum that recognizes both human and murine E4F proteins. (b) Val5 cells were transfected with 4 mg of pCMV-FAP3, encoding for the murine homologue of E4F (FAP3) or with the same amount of pcDNA3 then immunoprecipitation and Western blotting was performed as described for (a). (c) U2OS cells were transfected with 10 mg of pcDNA3HAE4F2.5K (HA-E4F2.5K) or pcDNA3 and p53 was immunoprecipitated with an amino terminus-speci®c antibody (DO-1). After SDS ± PAGE, the blotted proteins were probed with anti-HA antibody. (d) Endogenous E4F was immunoprecipitated from U2OS cells with anti-N4 antiserum (N4), speci®c for the amino terminus of E4F, or with preimmune sera (IgG) as control and immunocomplexes were analysed in Western blot by using the DO-1 antibody. T, total cell lysate; IP, immunoprecipitation performed with the indicated antibody (Shaulian et al., 1992) . As shown in Figure 4a , neither HA-E4F2.5K nor HA-E4FD350 signi®cantly aected the transactivation ability of p53 (lanes 4 and 5), whereas p53 Ct almost completely inhibited that function (lane 3). The expression levels of each proteins were comparable as judged by Western blotting (Figure 4b ). The averaged results of three independent experiments are plotted in Figure 4c . We consistently observed a slight repression by overexpressing the full-length E4F even when it was cotransfected with reporter constructs containing the SV40 or the thymidine kinase promoters in the absence of p53 (not shown). These ®ndings therefore suggest that the interaction between E4F and p53 does not aect the transactivation capability of p53.
Binding to p53 requires amino acids 521 ± 580 of E4F
The previous assays demonstrated that residues speci®c to p120E4F are required for p53 binding. To better de®ne this region, several E4FD350 deletions were expressed as GST-fusions and used for pull down assay with in vitro translated wt p53 ( Figure 5 ). Deletion of the last 89 amino acids (GST-E4FD350/NcoI) had no eect on p53 binding (Figure 5a , lane 4), while removal of residues 428 ± 783, including the entire central zinc®nger domain (GST-E4FD350/S®I), completely abolished the interaction (lane 6). A construct lacking amino acids from 552 to 783 (GST-E4FD350/PstI) was severly impaired in its ability to associate with in vitro translated p53 (lane 5), suggesting that residues in the last zinc-®nger motif (comprising amino acids 548 ± 568) might be involved in mediating the interaction. Indeed, two fusions that contain the intact last zinc®nger motif, GST-E4FD350 ± 580 and GST-E4FD521 strongly bound to p53 (lanes 7 and 9), while no interaction was detected with an E4F deletion lacking the entire zinc-®nger domain and sequences upstream of it (GST-E4FD581, lane 8). Similar results were obtained when the dierent deletions were assayed in the yeast two-hybrid system (not shown). These data indicate that p120E4F contacts p53 through a carboxyterminal region located between amino acids 521 and 580.
Ectopic expression of E4F requires wt p53 for growth suppression
Although cellular genes speci®cally regulated by E4F proteins are unknown, it was recently shown that p120E4F can mediate a growth arrest in NIH3T3 cells, suggesting an important role for this protein in cell growth control (Fernandes et al., 1998) . In order to test the biological relevance of the complex formation S-labeled, in vitro translated full-length wt p53 and carboxy terminally truncated derivatives were incubated for 1 h with 2 mg of GST-E4FD350 or GST prebound on GSHSepharose beads. The bound proteins were resolved on SDS ± polyacrilamide gels (12.5%, left panel, 15% right panel) and visualized by autoradiography. (b) Schematic representation of the various p53 constructs used in the pull down assay and a summary of their binding properties to GST-E4FD350. All the numbers refer to amino acids. The functional domains of p53 are indicated between p53 and E4F, we overexpressed E4F in various human and mouse cell lines, harboring wildtype, mutant or lacking endogenous p53.
Full-length E4F (E4F2.5K) and various PCRgenerated deletions were cloned in frame in pcDNA3HA vector (Figure 6a ) and tested for their expression levels and subcellular localization. Transient transfections in U2OS cells revealed that all the constructs expressed similar amounts of proteins, as shown by Western blot analysis in Figure 6b . The subcellular localization of the translated proteins, assayed following microinjection by immunofluorescence with anti-HA antibody, is presented in Figure 6c . HA-E4F2.5K, as well as the carboxy terminal deletions HA-E4F/NcoI and HA-E4F/PstI, displayed heterogeneous subcellular distributions: some cells showed only nuclear localization whereas others revealed both nuclear and cytoplasmic staining. In contrast, HA-E4FD350, which lacks the amino terminal half of p120E4F, was exclusively nuclear. The growth inhibition by p120E4F is p53-dependent P Sandy et al
To address the biological role of p120E4F, human cell lines expressing wt p53 (U2OS) or lacking p53 (SaOS-2) were transfected with pcDNA3HAE4F2.5K, pcDNA3HAE4FD350 or vector alone and tested for colony formation ability after 2 weeks of selection in G418-containing medium. The results of three independent experiments are shown in Figure 7a . A similar reduction (*50%) in colony numbers was observed both with HA-E4F2.5K and HA-E4FD350 in SaOS-2 cells as compared to the positive control empty vector (100%). In contrast, a much stronger growth suppression eect was detected when the E4F constructs were transfected into U2OS cells, thus suggesting the involvement of wt p53.
To more ®rmly establish the potential role of wt p53 in the p120E4F-mediated growth suppression, we microinjected a panel of murine cell lines expressing wt p53 (NIH3T3) mutant p53 (Val5, maintained at 378C) or in which both p53 alleles are deleted (Balb/c (10)1) and tested the inhibition of S phase entry by bromodeoxyuridine (BrdU) incorporation assay. Asynchronously growing cells were microinjected as previously described with the various E4F constructs together with a plasmid expressing the green¯uorescent protein (GFP) under the control of a CMV-promoter (pGFP-C1, Clontech) as a marker gene. Growth suppression in microinjected cells (GFP-positive) was measured by scoring the relative fraction of cells in S phase (anti-BrdUpositive) with respect to uninjected cells in adjacent ®elds .
The results of at least four independent experiments are reported in Figure 7b . Enforced expression of HA-E4F2.5K blocked S phase entry in NIH3T3 cells but neither in Balb/c (10)1, which lack endogenous p53, nor in Val 5 cells at the non-permissive temperature. Similar results were observed with HA-E4F/NcoI and HA-E4FD350, both of them being able to associate with p53. Under the same conditions a similar growth suppression eect was observed by injecting wt p53 (not shown). In contrast, overexpression of the carboxy terminally truncated construct HA-E4F/PstI, which is de®cient in binding to p53, did not inhibit S phase entry in any of the cell lines tested. In all the experiments performed, injection of the empty vector (pcDNA3HA) together with pGFP-C1 had no any relevant eect.
To further prove the involvement of wt p53 in the p120E4F-mediated growth suppression, Balb/c (10)1 cells were coinjected with HA-E4F2.5K or HA-E4F/ PstI and limiting amount of p53 together with pGFP-C1 as marker and processed as described above. Overexpression of wt p53 alone resulted in a moderate growth inhibition (18%, Figure 7c ) that was not aected by the coexpression of HA-E4F/PstI. Microinjection of HA-E4F2.5K alone had no eect on cell growth, while coinjection of wt p53 and HA-E4F2.5K resulted in a 30% inhibition of S phase entry. The results obtained by colony formation assays in human cell lines, together with the data from microinjection experiments in mouse cells, demonstrate that ectopic expression of p120E4F causes a growth suppression and cell cycle arrest that depends upon the presence of wt p53 and the ability of p120E4F to associate with it.
Discussion
In this report we demonstrated that the E1A-regulated transcription factor p120E4F associates with p53 and depends upon wild-type p53 to exert its growth inhibitory eect in human and murine cells. The growth inhibition by p120E4F is p53-dependent P Sandy et al
Originally identi®ed in HeLa cells as DNA-binding activities that recognize the adenovirus E4 promoter in an E1A-dependent manner (Raychaudhuri et al., 1987) , E4F factors are low abundance zinc-®nger proteins that are expressed in a wide range of tissues (Rooney et al., 1998b) . Although their cellular target genes are unknown, current evidence suggests that transcriptional regulation by E4F proteins may be somewhat complex. Within cells, two forms of E4F are present with distinct transcriptional activities. The full-length p120E4F protein behaves as a transcriptional repressor of the E4 promoter in the absence of E1A, and introduction of the viral protein relieves the repression (Fernandes and Rooney, 1997) . In contrast, p50E4F, a proteolytic fragment of p120E4F that contains the amino terminal zinc-®nger domain required for E4 promoter recognition, is able to activate that promoter, but only in the presence of E1A (Fernandes and Rooney, 1997) . E1A regulates the transcriptional activities of both forms of E4F by inducing their phosphorylation at critical residues involved in DNAbinding (Fernandes and Rooney, 1997; Fognani et al., 1993; Raychaudhuri et al., 1989) .
Interestingly, FAP3, the murine homologue of E4F, is processed in a similar fashion (Fernandes and Rooney, 1997; Fognani et al., 1993) and was originally isolated based upon its ability to bind to a completely dierent DNA sequence; a negative regulatory element within the adenovirus E1A promoter/enhancer (Fognani et al., 1993) . When overexpressed, FAP3 speci®cally repressed the transcription of a reporter gene controlled by that promoter (Fognani et al., 1993) . Moreover, whereas binding to the E4F consensus sequence requires only the amino terminal zinc-®nger domain, recognition of the FAP3 site may occur through the central domain (Fernandes and Rooney, 1997; Fognani et al., 1993; Rooney et al., 1998a) . Thus, depending upon their proteolytic form and phosphorylation state, E4F proteins may participate in a number of independent transcriptional and physiological responses.
One physiological eect that occurs with ectopic expression of p120E4F in murine ®broblasts is a cell cycle arrest near the G1/S transition that correlates with a transcriptional-independent increase in the p21
Waf1,Cip1 and p27 Kip1 protein levels (Fernandes et al., 1998) . Notably, this eect was observed only with the full-length p120E4F and not with the amino terminal form p50E4F, indicating a speci®c involvement of the carboxy-terminal half of the protein in this function.
In searching for p53-interacting molecules, we isolated several E4F clones in the yeast two-hybrid screening and all of them contained sequences encoding for the carboxy-terminal part of p120E4F, including the central zinc-®nger domain. The binding site for p53 was localized to a region around the fourth zinc-®nger motif. By coimmunoprecipitating wt and mutant p53
Figure 7 E4F inhibits S phase entry in a p53-dependent manner. (a) Colony formation assay in human cell lines. SaOS-2 and U2OS cells were transfected at low density with 1 mg of plasmid DNA and grown in the presence of 500 mg/ml G418 for 2 weeks. After selection the surviving colonies were ®xed then stained with 10% Giemsa. The numbers represent the result of three independent experiments and calculated as compared to the number of colonies obtained by transfecting the empty vector (pcDNA3, 100%). (b) Growth inhibition assay by microinjection of E4F constructs in murine cell lines. NIH3T3, Balb/c (10)1 and Val5 cells maintained at 378C were coinjected with the indicated E4F expression vectors (50 ng/ml) and pGFP-C1 (25 ng/ml), used as marker. Twenty hours after microinjection cells were pulsed with 50 mM bromodeoxyuridine (BrdU) for 4 h, then ®xed and stained with anti-BrdU antibody. The results are the mean of at least four independent experiments and were obtained by scoring more than 500 cells for each microinjected construct in every cell line. The percentage of S phase inhibition was calculated with the following formula: ((percentage of cells in S phase in the background ± percentage of cells in S phase in the microinjected cells)/(percentage of cells in S phase in the background))6100. (c) Growth inhibition assay by coinjection of HA-E4F2.5K (50 ng/ml) or HA-E4F/PstI (50 ng/ml) and limiting amount (5 ng/ml) of wt p53 in Balb/c (10)1 cells. Inhibition of S phase entry was measured and calculated as described in (b). The data obtained from at least four independent experiments. Error bars indicate standard deviation from the mean
The growth inhibition by p120E4F is p53-dependent P Sandy et al with transiently transfected E4F, or its murine homologue, FAP3, we demonstrated that the interaction occurs in vivo both in human and murine cell lines. More importantly, we have shown that endogenous p53 and p120E4F proteins also associate, suggesting that the resulting complex may play an actual role in cell proliferation or cell cycle control.
To establish the biological relevance of this interaction, we performed microinjection experiments and colony formation assays by using a panel of murine and human cell lines expressing wt or mutant p53 or lacking endogenous p53. In the microinjection experiments enforced expression of full-length p120E4F or the short carboxy-terminal deletion E4F/NcoI inhibited S phase entry in cells harboring wt p53, whereas expression of E4F/PstI, a deletion inecient to bind to p53, had no eect. In contrast, no inhibition of S phase entry was observed in p53 null cells (Balb/c (10)1) or in cells expressing mutant p53 (Val5, 378C) . Overexpression of p120E4F greatly inhibited colony formation by human cells harboring wt p53 (U2OS), although a 50% reduction was observed with p53 null cells (SaOS-2) as well. This type of assay, however, allows the detection of a growth suppression eect in its more general sense (growth arrest and/or apoptosis), therefore the 50% colony reduction achieved in SaOS-2 cells may re¯ect an involvement of p120E4F in a p53-independent mechanism that is inoperative in the transient microinjection assay. Nevertheless, the results clearly show that p53 and p120E4F interact and strongly repress cell proliferation.
One apparent discrepancy with previous results that should be noted, is that the role of p53 in mediating p120E4F growth suppression was initially excluded based upon the observation that cotransfection of a dominant negative p53 mutant with p120E4F had no eect on colony reduction in NIH3T3 cells (Fernandes et al., 1998) . However, the design of those experiments did not take into account the ability of p120E4F to physically interact with wt and mutant p53. Thus, given the relative amounts of transfected p120E4F and mutant p53 constructs used by Fernandes et al. (1998) , it is likely that the excess levels of p120E4F were suciently high to titre out the mutant p53 protein and prevent its abrogation of wt p53 function.
p53 is a transcription factor that binds DNA in a sequence-speci®c manner with its central domain located between amino acids 102 and 292 (Pavletich et al., 1993; Bargonetti et al., 1993; Wang et al., 1993) . Here we demonstrated that p120E4F contacts p53 in its DNA-binding region in vitro and residues from 256 ± 294 of p53 are involved in mediating the interaction (Figure 3) . Interestingly, we observed a correlation between the quaternary structure of p53 and its ability to associate with p120E4F, suggesting a complex regulation of protein ± protein interaction. Although p120E4F binds to the end of the core domain of p53, this association does not aect the transactivation ability of p53 in vivo (Figure 4 ). This may be due to the fact that under the experimental conditions used, only a small fraction of p53 is bound to p120E4F, allowing unbound p53 to activate its reporter. Alternatively, the complex formation does not aect the DNA-binding capability of p53. Further investigations are required to distinguish between these possibilities.
Our evidence, that p120E4F can induce a p53-dependent block of cell proliferation without having an obvious eect on p53 transactivation function is consistent with the previous observation that elevated p21 protein levels in p120E4F-arrested cells occurred independently of an increase in p21 gene transcription (Fernandes et al., 1998) . This suggests that the p120E4F-mediated growth suppression may involve a number of target genes that are not directly regulated through consensus p53-binding sequences, rather through E4F or FAP3 sites.
We note that in both the colony formation and the microinjection assays, the truncated E4FD350 protein, which lacks the amino-terminal zinc-®nger domain and therefore fails to bind the E4F consensus sequence (Fernandes and Rooney, 1997) , was sufficient to induce growth inhibition both in human and murine cells. This suggests that cellular target genes of p120E4F responsible for the growth arrest eect may contain the FAP3 site. However, it is possible that p120E4F mediates this eect solely by bridging other proteins and may not require any DNA-binding function.
How p53 ®ts into this scenario is not yet clear. Control of gene expression generally requires the interaction of multiple factors, including several activators, coactivators, repressors and basal factors to stabilize the transcriptional machinery and determine its speci®city. It is conceivable that p53 may act as a p120E4F-cofactor, to regulate the dierential recognition of alternative DNA-binding sites for E4F proteins (Fernandes and Rooney, 1997; Fognani et al., 1993) or the association of p120E4F with other factors in the transcriptional complex. Alternatively, E4F may be involved in modulating the transcriptional repression function of p53. Notably, although mutant p53 can still associate with E4F, the complex is not functional in terms of growth suppression. This indicates that the conformation of p53 in the complex is important for the E4F function, and may re¯ect a requirement to bridge p120E4F to other factors that recognize only wt p53. Several wt p53-binding proteins are also able to interact with mutant forms of p53, but, as with p120E4F, the mutant proteins lack the ability to regulate the activity of these partners (Wang et al., 1995) . The potential role of p53 as an E4F-cofactor may be particularly relevant when cells are exposed to stimuli which normally induce p53, since cells lacking the p53 checkpoint are seriously de®cient in the p120E4F-dependent response.
Truncations at the carboxy-terminal end of p120E4F, which impair the binding of p53, nullify its growth inhibitory eect. Thus it would be of interest to look for the presence of genetic alterations in the E4F gene, mapped on chromosome 16p13.3 (Rooney et al., 1998b; Saccone et al., 1998) , within tumor cells that express wt p53.
A better understanding of the role of the p53/E4F complex requires characterization of other factors that associate with the carboxy half of p120E4F and most of all, the identi®cation of E4F cellular target genes. Our evidence that p53 can physically associate with E4F and is required for its growth suppression eect, suggests that p120E4F is an important element within the complex network of p53 checkpoint functions.
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Materials and methods
Cell lines and transfections
All the cell lines employed were routinely cultured at 378C in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml). The Balb/c (10)1 cell line does not contain endogenous p53 (Harvey and Levine, 1991) ; the Val5 cell line is a Balb/c (10)1 derivative, stably expressing the murine p53Val135 carrying a temperature-sensitive mutation at Valine 135, which behaves as mutant at 378C and as wt at 328C (Ginsberg et al., 1991; Wu and Levine, 1994) . Transfections were performed by the standard calcium phosphate precipitate method. For transient transfections cells were seeded 8 ± 12 h before transfection and further processed 24 ± 36 h after removing the precipitate. CAT-reporter assays were performed by routine procedures. For colony formation assays cells were seeded at low density in 3 cm dishes and transfected with 1 mg of the indicated vectors. One day posttransfection cells were trypsinized and replated in 10 cm dishes in a medium containing 500 mg/ml geneticin (G418-sulfate, GIBCO). After 2 weeks of selection, the surviving colonies were ®xed with 3% paraformaldehyde and stained with 10% Giemsa. The number of the empty vector-expressing colonies was scored as 100%.
Plasmids
To generate the LexA-fusion constructs, human p53H175 and wt p53 cDNAs were PCR-ampli®ed between aa 74 and aa 393 and cloned in-frame into pLexA202 (Gyuris et al., 1993) . To construct pcDNA3HAE4FD350, the E4F cDNA (from aa 350 to aa 783), isolated from the two-hybrid screening was inserted into pcDNA3 (Invitrogen) downstream to a START codon and a contiguous HA-epitope. To generate pcDNA3HAE4FD60, an E4F cDNA (aa 60 to aa 783) isolated from a human placental cDNA library in lambda ZapII (Stratagene) screened with E4FD350 was cloned into pcDNA3HA. pcDNA3HAE4F2.5K was generated by subcloning E4F2.5K from pCMVs-E4F2.5K (Fernandes and Rooney, 1997) into pcDNA3HA. pCMV-FAP3 has been already described (Fognani et al., 1993) . All the carboxyterminal truncations of E4F as well as E4FD581 were obtained by PCR-ampli®cation. For the GST-pull down assay E4FD581, E4FD350 and carboxy-terminally truncated derivatives were subcloned into pGEX4T-1 (Pharmacia) as EcoRI/XhoI fragments. E4FD521, a shorter carboxy-terminal fragment of E4F (aa 521 ± 783), obtained from the placental cDNA library screening, was subcloned into pGEX4T-2 (Pharmacia) as a BamHI/XhoI fragment. To construct pcDNA3HAp53Ct, the human p53 fragment from aa 294 ± 393 was PCR-ampli®ed and cloned downstream of the HA epitope into pcDNA3. p53D265 was obtained from the yeast two-hybrid screen and subcloned into pcDNA3HA. The p53 truncations tr355 and tr338 (Tarunina and Jenkins, 1993) were cloned respectively in pBSK (Stratagene) and pSP6 (Promega). The truncation tr298 was produced by PCR and cloned into pBSK. pRcCMVhp53H175 and pRcCMVhp53H273 have been already described (Hinds et al., 1990) . pcDNA3wtp53 contains the full-length, human wtp53 cDNA cloned as an EcoRI fragment in pcDNA3. The p53-reporter plasmid employed for CAT assays, PG13CAT, has been described previously (Kern et al., 1992) . All the PCR-ampli®ed products were checked by sequence analysis.
Yeast two-hybrid screen p53H175 fused to the LexA DNA-binding domain was introduced into the EGY48 (MAT a trp1 ura3 his3 LEU2::pLEXAop6-LEU2) yeast strain (Gyuris et al., 1993) , previously transformed with the pSH1834 plasmid, and selected on Ura-His-plates. This strain was transformed with a cDNA library from human W138 ®broblasts made quiescent by serum starvation and contact inhibition cloned into the pJG4-5 plasmid (Gyuris et al., 1993; Lamphere et al., 1997) . Approximately 3.5610 6 primary yeast transformants were selected on plates Ura-His-Trp-and then pooled together. The interaction was performed by plating about 10610 6 clones from the pooled library onto Ura-His-LeuTrp-plates containing galactose. After 3 days, around 200 clones that grew and turned blue when subjected to b-gal expression assay were puri®ed and further processed for the isolation of the plasmid. Plasmids containing the cDNA were selected in the E. coli B290 (Gyuris et al., 1993) strain and classi®ed through restriction analysis and Southern dot blot.
GST-pull down assay
The indicated Glutathione S-transferase (GST)-fusion proteins were produced in BL21 bacteria and puri®ed by conventional procedures. Brie¯y, overnight cultures were diluted 1 : 10 and grown to OD 600 =0.7, then the production of the fusion proteins was induced by the addition of 250 mM isopropylthiogalactopyranoside (IPTG) at 308C for 4 ± 6 h. The cells were lysed by sonication on ice in PBS containing 1% Triton X-100, 0.2% SDS, 0.5% NP-40, 0.1% Tween-20, 1 mM phenylmethylsulfonyl¯uoride (PMSF) and 10 mg/ml of each of chymostatin, leupeptin, antipain and pepstatin. The proteins were puri®ed with Glutathione Sepharose 4B beads (Pharmacia) according to the manufacturer's instructions and the concentrations were estimated after SDS ± PAGE. In the pull down assay 2 mg of GST-fusion protein or GST was incubated with 35 S-labeled in vitro translated protein (TNTcoupled reticulocyte lysate system, Promega) in 200 ml of binding buer (150 mM NaCl, 20 mM HEPES pH 7.5, 10% glycerol, 0.05% NP-40) for 1 h at 48C. After washing, the bound complexes were solubilized with 26 Laemmli sample buer and loaded onto an SDS ± polyacrylamide gel. 25% of the amounts of in vitro translated protein used for the binding reaction was loaded as input. The bands were visualized by autoradiography.
Immunoprecipitation and Western blot analysis
Subcon¯uent cells seeded on 10 cm diameter Petri dishes were transfected with the indicated expression vectors by the conventional calcium phosphate procedure. Thirty-six hours posttransfection cells were washed with ice-cold phosphate buered saline (PBS), then harvested in 1 ml of ice-cold lysis buer as previously described (Muller et al., 1997) . The lysis was performed at 48C for 30 min then the lysates were clari®ed by centrifugation. Two mg of puri®ed antibodies or 2 ml of hybridoma supernatant (anti-p53 antibodies Pab 240 and Pab 246) prebound overnight to 20 ml of Protein A Sepharose CL-4B or GammaBind G Sepharose beads (both from Pharmacia) were then added to each sample and incubation at 48C was continued for 6 h. The beads were then washed three times in 1 ml of ice-cold lysis buer and the bound proteins were solubilized by addition of 20 ml of 26 Laemmli sample buer. Western blotting was performed according to standard procedures by using the following primary antibodies: 12CA5 (anti-HA, Boehringer, Mannheim), anti-FAP3 (Fognani et al., 1997) , DO-1 (anti-p53), N4 (anti-E4F; Fernandes and Rooney, 1993) , anti-GST (Pharmacia). The bands were visualized by enhanced chemiluminescence (Amersham).
Microinjection, immuno¯uorescence and BrdU incorporation assay
Cells cultured in DMEM containing 10% FCS were grown on coverslips in 35 mm Petri dishes. After 24 h of incubation at 378C, cells were microinjected with the various plasmids by the Automated Injection System
